Prestige Biopharma executives buy shares as biosimilar strategy advances
AI Summary- Ko Sang-seok bought Prestige Biopharma shares on the open market.
- 45,600 shares were purchased last month, following Park So-yeon’s 213,500 shares.
- Prestige Biopharma IDC is developing drugs, delivery platforms and cancer diagnostics.